Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...

Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage ...

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Within the peer analysis summary, vital metrics for Agios Pharmaceuticals, Recursion Pharmaceuticals and Apellis ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

If you haven’t lived underneath a rock for the past decade or so, you will have seen a lot of arguing in the media by ...

The support network that has emerged through the Mises Institute is really important. We feel like we’re all alone, but ...

For years, privacy-focused blockchains were seen as side projects with limited reach. That’s about to change with Zero Knowledge Proof (ZKP). Built as a privacy ...

It's a plot device beloved by science fiction: our entire universe might be a simulation running on some advanced ...